The Allergy Diagnostic segmentation by application distinguishes three principal use cases: clinical diagnosis, research & development, and point‑of‑care/home testing. Clinical diagnosis, which encompasses hospitals, specialty clinics and allergy centers, commands the largest share of the market, accounting for roughly 55 % of total revenues. Its dominance is driven by the high volume of physician‑ordered tests, reimbursement structures, and the need for comprehensive panels that guide therapeutic decisions. Research & development, representing about 25 % of the market, includes pharmaceutical companies, academic laboratories, and contract research organisations that employ diagnostic kits to validate new therapeutics or investigate immunological mechanisms. Although lower in absolute revenue, R&D activities stimulate innovation and sustain demand for next‑generation assay platforms. Point‑of‑care/home testing, the remaining 20 %, captures tests performed in primary‑care offices, urgent‑care settings and by consumers using at‑home kits. This segment is expanding rapidly due to decentralised care models and growing consumer awareness, yet it remains limited by regulatory constraints and lower test complexity. Together, these application categories shape the overall market size and growth trajectory.
